Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control

Table 1

Demographic, laboratory, and echocardiographic data after eight weeks of treatment.

	Group C	Group D	Group I	Group P	Group IP	value
BWt (g)	387 (375.8–401)^†, ‡, §, ‖	226 (215–293)	352 (320–370)^†, §	246.5 (236–255)	352 (329.5–366)^†, §	<0.001
HWt (g)	1.18 (1.15–1.27)^†, ‡, §	0.81 (0.77–0.85)^, ‡, ‖	1.07 (0.98–1.11)^, †, §	0.87 (0.80–0.92)^, ‡, ‖	1.09 (1.02–1.17)^†, §	<0.001
HWt/BWt (%)	0.31 (0.3–0.33)^†, §	0.39 (0.36–0.41)^, ‡, ‖	0.31 (0.3–0.34)^†, §	0.35 (0.33–0.39)^, ‡	0.32 (0.31–0.37)^†	0.002
Blood glucose (mg/dl)	142 (133–153)^†, §	443 (403–470)^, ‡, ‖	141 (89–149)^†, §	438 (417–505)^, ‡, ‖	119 (83–151)^†, §	<0.001
Lipid profile (mg/dl)
Total cholesterol	82.5 (77–91.5)	93 (85.25–103)	81.5 (72–86)	79.5 (71–81)	88 (84–90)	0.01
Triglyceride	65 (41–77.5)^†	145 (138–325.5)^∗	124 (86–140)^∗†	92.5 (74–137)^∗†	106 (65–145.5)^∗†	<0.001
HDL	74 (71.5–76.5)^†, ‡	60 (58–74)^∗, ‖	68 (60–72)^∗, ‖	69 (65–75)^‖	79 (74–81)^†, ‡, ‖	0.004
LDL	11.5 (11-12.5)	15 (10–17.25)	11 (10–13.25)	10 (10-11)	12 (10.25–13)	0.118
Echocardiographic variables
FAC (%)	61 (58–68)^†, §	38 (29–43)^∗, ‡, §, ‖	60 (53–62)^†	52 (45–56)^∗, †, ‖	63 (60–72)^†, §	<0.001
FS (%)	53 (49–54)^†, ‡, §	39 (37–43)^∗, ‖	45 (41–48)^∗	41 (34–45)^∗, ‖	53 (41–63)^†, §	0.0014
E/A ratio	1.8 (1.5–2.5)^†, §	0.9 (0.8–0.9)^∗, ‡, ‖	1.8 (1.2–1.9)^†, §	0.8 (0.7–0.8)^∗, ‡, ‖	1.7 (1.5–2.3)^†, §	<0.001

Data are presented as the median (IQR). values were calculated using a Kruskal-Wallis one-way analysis of variance on ranks. The Tukey test was used for multiple comparisons. BWt: body weight; HWt: heart weight; HDL: high-density lipoprotein; LDL: low-density lipoprotein; FAC: fractional area change; FS: fractional shortening; E/A: the ratio of the early (E) to late (A) ventricular filling velocities. versus group C, versus group D, versus group I, versus group P, and ^‖ versus group IP.